Finally, we observed that ERK5 inhibition potentiated TRAIL cytotoxicity in a panel of TRAIL-resistant cancer cell lines (Fig. 1D), such as neuroblastoma (SK-N-AS), cervical (HeLa), non-small cell lung (A549), and prostate (LnCaP) cancer cells [28–31]. This evidence concerns the gene TNFSF10 and neuroblastoma.